Lv5
1015 积分 2020-08-10 加入
给刘宇宁的粉丝一篇文献吧
Pathophysiology of progressive nephropathies
2天前
已完结
A Step Forward — Obinutuzumab for Membranous Nephropathy
18天前
已完结
Targeting CD20 in Primary Membranous Nephropathy Serologically and Histologically Negative for PLA2R: Is Obinutuzumab Superior to Rituximab?
19天前
已完结
奥妥珠单抗治疗膜性肾病并长期随访1例
19天前
已完结
奥妥珠单抗在膜性肾病中的临床应用进展
19天前
已完结
Obinutuzumab: a new frontier in the treatment of refractory idiopathic membranous nephropathy
19天前
已完结
Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases
19天前
已完结
Obinutuzumab in the treatment of PLA2R-positive membranous glomerulonephritis resistant to treatment
19天前
已完结
Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy
19天前
已完结
Association between anti-rituximab antibodies and treatment efficacy of rituximab in membranous nephropathy
20天前
已完结
皖公网安备34019202002308
